Overview

Webcast MannKind at Bank of America Merrill Lynch Health Care Conference (Replay) 05/15/12 at 10:40 a.m. PT

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links Corporate Governance Annual Reports Quarterly Reports 2012 Annual Meeting Materials Receive E-mail Alerts Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

MNKD (Common Stock) Exchange NASDAQ GM (US Dollar) Price $1.83 Change (%)   0.02 (1.10%) Volume 1,923,000 Data as of 05/16/12 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Date Title   05/09/12 MannKind Corporation Reports 2012 First Quarter Financial Results - Conference Call to Begin Today at 5:00 PM EDT - VALENCIA, Calif.--(BUSINESS WIRE)--May. 9, 2012-- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2012. For the first quarter of 2012, total operating expenses were $33.9 million, compared to $38.1 million for the first quarter of 2011, a decrease of $4.1 million. Research and development (R&D) expenses were ...  05/08/12 MannKind to Present at Bank of America Merrill Lynch 2012 Health Care Conference VALENCIA, Calif.--(BUSINESS WIRE)--May. 8, 2012-- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 10:40 am Pacific Daylight Time at the Encore at the Wynn in Las Vegas, Nevada. Interested parties can access a link to the live webcast of...  05/02/12 MannKind Corporation to Hold 2012 First Quarter Financial Results Conference Call on May 9, 2012 VALENCIA, Calif.--(BUSINESS WIRE)--May. 2, 2012-- MannKind Corporation (Nasdaq: MNKD) will release its 2012 first quarter financial results on Wednesday, May 9, 2012 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2012. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann, President and C...  04/30/12 Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases SALT LAKE CITY & VALENCIA, Calif.--(BUSINESS WIRE)--Apr. 30, 2012-- Tolero Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, and MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes and cancer, today announced a license agreement granting Tolero exclusive worldwide rig...

Print |  E-mail Page |  RSS Feeds |  E-mail Alerts |  IR Contacts |  Tear Sheet